Is modulating translation a therapeutic option for Huntington's disease? - Wikidata - awgldk - TriplyDB

Is modulating translation a therapeutic option for Huntington's disease?

Is modulating translation a therapeutic option for Huntington's disease?

http://www.wikidata.org/entity/Q41807512

about

Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein.

P2860

Q46236725-933BD04A-06E4-4F20-8B5C-5352D87D3A79

P2860

Is modulating translation a therapeutic option for Huntington's disease?

http://www.wikidata.org/entity/Q41807512

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Is modulating translation a therapeutic option for Huntington's disease?

@en

type

label

Is modulating translation a therapeutic option for Huntington's disease?

@en

prefLabel

Is modulating translation a therapeutic option for Huntington's disease?

@en

P1433

Q41807512-51535241-9D1E-4F7B-833F-D6B4B0DCA3E7

P1476

Q41807512-9E59149C-3419-4B9B-A96D-3DAA831A6550

P2093

Q41807512-C8E7CF60-C3DA-4BBC-A344-B2F7C0916C34

P2860

Q41807512-070BC38B-8629-4B56-AD60-A0488241CCAF

Q41807512-1373673B-71A3-4C1F-9CE2-2B13AB20BBAC

Q41807512-1F3DC499-C7EE-4D47-8C20-7395DDAD0133

Q41807512-2152782F-D5B5-47AA-B149-23F717FFF9A3

Q41807512-315EDF2E-36F9-4E7B-AD9E-83C254E36E91

Q41807512-4EBC239B-C62E-4AB3-90EE-FBB67254730A

Q41807512-684B3EA6-2E03-411B-88D6-C6ADF1CB252A

Q41807512-76EBF2DC-AC26-4003-93A0-3D46B12E8CD6

Q41807512-8277C3C6-26EF-43ED-92E9-81F445A3F58B

Q41807512-91486600-CD2D-4D5C-8249-EF46593C7222

P304

Q41807512-04430814-C8C7-4BEE-B90D-6B993B6BD573

P31

Q41807512-BFCBD66E-12C6-4C98-B031-BCF7457A6A27

P356

Q41807512-A5B86CFF-631B-4DBF-B1F6-C50B748170A6

P433

Q41807512-BDEBE701-D4EA-41DD-8A67-C86211D1E58B

P478

Q41807512-FC2A16BA-6C8A-4F68-91E6-D5492C2DB7C1

P577

Q41807512-D2CFFCE8-D814-424D-99C4-6D11FDDB3889

P698

Q41807512-FC486C98-8416-4695-B790-A5C07A57D760

P921

Q41807512-D9478CFA-3BD9-4842-8E9F-283A81854694

P932

Q41807512-435D3219-9E11-46B0-A4B4-258A145E0DEA

P356

P1433

Neurodegenerative disease management

P1476

Is modulating translation a therapeutic option for Huntington's disease?

@en

P2093

Flaviano Giorgini

http://www.w3.org/2001/XMLSchema#string

P2860

LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.

A role for huntington disease protein in dendritic RNA granules

The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation

Huntington's disease: the challenge for cell biologists.

RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation.

4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila.

Transcriptional abnormalities in Huntington disease.

Huntingtin-protein interactions and the pathogenesis of Huntington's disease.

P304

89-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/NMT.11.12

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24527061

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

3920366

http://www.w3.org/2001/XMLSchema#string